M
Michael C. Jensen
Researcher at Seattle Children's Research Institute
Publications - 57
Citations - 2743
Michael C. Jensen is an academic researcher from Seattle Children's Research Institute. The author has contributed to research in topics: Chimeric antigen receptor & T cell. The author has an hindex of 21, co-authored 57 publications receiving 2247 citations. Previous affiliations of Michael C. Jensen include Beckman Research Institute & Fred Hutchinson Cancer Research Center.
Papers
More filters
Journal ArticleDOI
Receptor Affinity and Extracellular Domain Modifications Affect Tumor Recognition by ROR1-Specific Chimeric Antigen Receptor T Cells
Michael Hudecek,Maria Teresa Lupo-Stanghellini,Paula L. Kosasih,Daniel Sommermeyer,Michael C. Jensen,Christoph Rader,Stanley R. Riddell +6 more
TL;DR: T cells modified with an optimized ROR1-CAR have significant antitumor efficacy in a preclinical model in vivo, suggesting they may be useful to treat R OR1+ tumors in clinical applications.
Journal ArticleDOI
T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia
Armen Mardiros,Cedric Dos Santos,Tinisha McDonald,Christine E. Brown,Xiuli Wang,L. Elizabeth Budde,Lauren Hoffman,Brenda Aguilar,Wen-Chung Chang,William Bretzlaff,Brenda Chang,Mahesh Jonnalagadda,Renate Starr,Julie R. Ostberg,Michael C. Jensen,Ravi Bhatia,Stephen J. Forman +16 more
TL;DR: The results suggest that CD123 CAR T cells are a promising immunotherapy for the treatment of high-risk AML.
Journal ArticleDOI
Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma.
Khun Visith Keu,Timothy H. Witney,Timothy H. Witney,Shahriar S. Yaghoubi,Jarrett Rosenberg,Anita Kurien,Rachel Magnusson,John W Williams,Frezghi Habte,Jamie Wagner,Stephen J. Forman,Christine E. Brown,Martin Allen-Auerbach,Johannes Czernin,Winson Tang,Michael C. Jensen,Behnam Badie,Sanjiv S. Gambhir +17 more
TL;DR: PET gene reporter imaging can be used to monitor the trafficking of therapeutic cytotoxic T cells in glioma patients and noninvasive positron emission tomography imaging with HSV1-tk reporter gene expression present in CAR-engineered CTLs is shown to be safe and enabled the longitudinal imaging of T cells stably transfected with a PET reporter gene in patients.
Journal ArticleDOI
Phase 1 studies of central memory–derived CD19 CAR T–cell therapy following autologous HSCT in patients with B-cell NHL
Xiuli Wang,Leslie Popplewell,Jamie Wagner,Araceli Naranjo,M. Suzette Blanchard,Michelle Mott,Adam Norris,Ching Lam W Wong,Ryan Urak,Wen-Chung Chang,Samer K. Khaled,Tanya Siddiqi,Lihua E. Budde,Jingying Xu,Brenda Chang,Nikita Gidwaney,Sandra H. Thomas,Laurence J.N. Cooper,Stanley R. Riddell,Christine E. Brown,Michael C. Jensen,Stephen J. Forman +21 more
TL;DR: Data from 2 safety/feasibility studies demonstrating the safety and feasibility of CD19 CAR TCM therapy after HSCT are presented, investigating different T-cell populations and CAR constructs.
Journal ArticleDOI
Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells.
TL;DR: Research topics in the laboratories that focus on the design and implementation of ACT with CAR‐modified T cells include cell intrinsic properties of distinct T‐cell subsets that may facilitate preparing therapeutic T‐ cell products of defined composition for reproducible efficacy and safety, the design of tumor targeting receptors that optimize signaling of T-cell effector functions and facilitate tracking of migration of CAR‐ modified T cells in vivo.